<DOC>
	<DOCNO>NCT00544414</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving combination chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Radiation therapy use high-energy x-ray kill tumor cell . Drugs gemcitabine cisplatin may make tumor cell sensitive radiation therapy . Giving combination chemotherapy surgery radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give chemotherapy follow surgery , chemotherapy , radiation therapy work treat patient locally advanced head neck cancer .</brief_summary>
	<brief_title>Chemotherapy Followed Surgery , Chemotherapy , Radiation Therapy Treating Patients With Locally Advanced Head And Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess complete overall response rate neoadjuvant docetaxel , cisplatin , fluorouracil , leucovorin calcium previously untreated patient local regionally advanced head neck cancer . - To evaluate feasibility multimodality treatment approach goal reduce long-term sequela . - To evaluate prospectively , impact neoadjuvant chemotherapy , concurrent chemoradiotherapy , organ preservation surgery overall survival , time progression , pattern disease recurrence patient . - To evaluate prospectively , biochemical correlate response prognosis , include marker thymidylate synthetase , ribonucleotide reductase , ERCC1 ( measure quantitative PCR ) , p53 ( evaluated IHC ) , HPV status apoptosis ( TUNEL assay ) . Secondary - To evaluate treatment-associated morbidity use quality life assessment tool . - To compare result diagnostic salivary cytology histopathology initial diagnosis well follow-up head neck cancer patient . - To evaluate tolerability combine chemoradiotherapy use gemcitabine cisplatin definitive surgery squamous cell carcinoma head neck . OUTLINE : Patients receive neoadjuvant induction chemotherapy comprise docetaxel IV 1 hour day 1 cisplatin IV , leucovorin IV , fluorouracil IV 24 hour day 1-4 . Induction chemotherapy repeat every 28 day 3 course absence disease progression unacceptable toxicity . Patients partial response primary site may undergo radical functional resection primary tumor within 3 week completion neoadjuvant therapy . Beginning within 4 week completion neoadjuvant therapy , patient persistent disease complete response chemotherapy primary neck undergo radiotherapy 5 day week 7 week receive gemcitabine hydrochloride IV 30 minute cisplatin IV 60 minute day 1 week radiotherapy absence disease progression unacceptable toxicity . Patients complete FACT-H &amp; N quality life questionnaire baseline completion neoadjuvant therapy . Tissue biopsy collect baseline , periodically therapy , surgery , radiotherapy . Tissue examine gene protein expression .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck , include follow subtypes : Oral cavity Oropharynx Hypopharynx Larynx Stage III IV disease Stage II carcinoma larynx , hypopharynx , base tongue allow Measurable disease Resectable disease , define tumor potentially curable surgery radiotherapy PATIENT CHARACTERISTICS : Karnofsky performance status ≥ 60 % ANC ≥ 1,500/μL Platelet count ≥ 100,000/μL Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min Bilirubin ≤ 1.5 mg/dL Transaminases alkaline phosphatase meet 1 follow criterion : ALT AST ≤ 2.5 time upper limit normal ( ULN ) AND alkaline phosphatase normal Alkaline phosphatase ≤ 4 time ULN AND ALT AST normal ALT AST &lt; 1.5 time ULN AND alkaline phosphatase &lt; 2.5 time ULN Free serious infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy allow purpose determine diseasefree overall survival except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient disease free 5 year No unstable angina , history congestive heart failure , acute myocardial infarction within past 6 month No current symptomatic , neurosensory neuromotor toxicity ≥ grade 2 No significant medical psychiatric condition incompatible protocol PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy head neck cancer</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
</DOC>